Insider Trades94 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Sell | HCA | Mike A Marks | EVP and CFO | 6,672 | $429.02 | $92.4B | -23.28% | +20.61% | $2.9M | +0.00% | — | Sell Now |
| Feb 13, 2026 | Sell | HCA | Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 10,000 | $387.28 | $92.4B | -23.28% | +20.61% | $3.9M | +0.00% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Erica Rossitto | SVP & Chief Nurse Executive | 418 | $502.05 | $92.4B | -23.28% | +20.61% | $209.9K | -3.86% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Mike A Marks | EVP and CFO | 1,690 | $502.05 | $92.4B | -23.28% | +20.61% | $848.5K | -33.63% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 3,006 | $502.05 | $92.4B | -23.28% | +20.61% | $1.5M | -25.35% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 3,501 | $502.05 | $92.4B | -23.28% | +20.61% | $1.8M | -9.84% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Christopher F. Wyatt | SVP & Controller | 5,034 | $504.39 | $92.4B | -23.28% | +20.61% | $2.5M | -5.15% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Jon M Foster | EVP and COO | 5,888 | $502.05 | $92.4B | -23.28% | +20.61% | $3.0M | -20.34% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Jennifer Berres | SVP & Chief Human Res. Officer | 10,535 | $511.59 | $92.4B | -23.28% | +20.61% | $5.4M | -18.00% | — | Sell Now |
| Feb 10, 2026 | Sell | HCA | Samuel N Hazen | CEO | 21,323 | $502.05 | $92.4B | -23.28% | +20.61% | $10.7M | -24.75% | — | Sell Now |
| Feb 5, 2026 | Buy | HCA | Christopher F. Wyatt | SVP & Controller | 16,344 | $269.14 | $92.4B | -23.28% | +20.61% | $4.4M | +5.38% | — | Sell Now |
| Feb 5, 2026 | Buy | HCA | Jon M Foster | EVP and COO | 45,406 | $271.72 | $92.4B | -23.28% | +20.61% | $12.3M | +45.19% | — | Sell Now |
| Feb 3, 2026 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 5,550 | $134.62 | $92.4B | -23.28% | +20.61% | $747.1K | -9.02% | — | Sell Now |
| Feb 3, 2026 | Sell | HCA | Samuel N Hazen | CEO | 42,877 | $501.04 | $92.4B | -23.28% | +20.61% | $21.5M | -12.25% | — | Sell Now |
| Jan 30, 2026 | Buy | HCA | Samuel N Hazen | CEO | 125,843 | $215.90 | $92.4B | -23.28% | +20.61% | $27.2M | +20.94% | — | Sell Now |
| Nov 14, 2025 | Sell | HCA | Samuel N Hazen | CEO | 14,830 | $472.65 | $92.4B | -23.28% | +20.61% | $7.0M | -31.48% | — | Sell Now |
| Nov 3, 2025 | Sell | HCA | Mike A Marks | EVP and CFO | 495 | $461.56 | $92.4B | -23.28% | +20.61% | $228.5K | -0.38% | — | Sell Now |
| Nov 3, 2025 | Sell | HCA | Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 26,340 | $350.89 | $92.4B | -23.28% | +20.61% | $9.2M | +0.00% | — | Sell Now |
| Oct 31, 2025 | Buy | HCA | Samuel N Hazen | CEO | 86,223 | $197.04 | $92.4B | -23.28% | +20.61% | $17.0M | +32.30% | — | Sell Now |
| Sep 4, 2025 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 21,840 | $293.63 | $92.4B | -23.28% | +20.61% | $6.4M | +0.00% | 10b5-1 | Sell Now |
| May 13, 2025 | Sell | HCA | Jon M Foster | EVP and COO | 22,008 | $263.43 | $92.4B | -23.28% | +20.61% | $5.8M | -8.73% | — | Sell Now |
| May 13, 2025 | Sell | HCA | Samuel N Hazen | CEO | 180,152 | $368.10 | $92.4B | -23.28% | +20.61% | $66.3M | +0.00% | — | Sell Now |
| May 6, 2025 | Sell | HCA | Mike A Marks | EVP and CFO | 1,582 | $356.70 | $92.4B | -23.28% | +20.61% | $564.3K | -0.65% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Mike A Marks | EVP and CFO | 172 | $321.92 | $92.4B | -23.28% | +20.61% | $55.4K | -26.96% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Sammie S Mosier | SVP & Chief Nurse Executive | 227 | $321.92 | $92.4B | -23.28% | +20.61% | $73.1K | -2.00% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Christopher F. Wyatt | SVP & Controller | 227 | $321.92 | $92.4B | -23.28% | +20.61% | $73.1K | -0.55% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 531 | $321.92 | $92.4B | -23.28% | +20.61% | $170.9K | -16.45% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 583 | $321.92 | $92.4B | -23.28% | +20.61% | $187.7K | -1.82% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Jon M Foster | EVP and COO | 684 | $321.92 | $92.4B | -23.28% | +20.61% | $220.2K | -2.36% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Samuel N Hazen | CEO | 4,742 | $321.92 | $92.4B | -23.28% | +20.61% | $1.5M | -6.21% | — | Sell Now |
| Feb 13, 2025 | Sell | HCA | Jennifer Berres | SVP & Chief Human Res. Officer | 9,940 | $322.56 | $92.4B | -23.28% | +20.61% | $3.2M | -13.98% | — | Sell Now |
| Feb 7, 2025 | Buy | HCA | Jennifer Berres | SVP & Chief Human Res. Officer | 18,527 | $190.48 | $92.4B | -23.28% | +20.61% | $3.5M | +6.67% | — | Sell Now |
| Feb 3, 2025 | Sell | HCA | Sammie S Mosier | SVP & Chief Nurse Executive | 41 | $334.30 | $92.4B | -23.28% | +20.61% | $13.7K | -0.39% | — | Sell Now |
| Nov 14, 2024 | Sell | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 1,474 | $357.99 | $92.4B | -23.28% | +20.61% | $527.7K | -13.49% | — | Sell Now |
| Nov 12, 2024 | Sell | HCA | Phillip G Billington | SVP-Internal Audit Services | 16,000 | $209.62 | $92.4B | -23.28% | +20.61% | $3.4M | +0.00% | — | Sell Now |
| Nov 12, 2024 | Buy | HCA | Erol R Akdamar | Group President | 33,157 | $180.91 | $92.4B | -23.28% | +20.61% | $6.0M | +23.01% | — | Sell Now |
| Nov 11, 2024 | Buy | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 7,946 | $248.41 | $92.4B | -23.28% | +20.61% | $2.0M | +5.85% | — | Sell Now |
| Sep 10, 2024 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 44,160 | $265.64 | $92.4B | -23.28% | +20.61% | $11.7M | +0.00% | 10b5-1 | Sell Now |
| Aug 8, 2024 | Sell | HCA | Mike A Marks | EVP and CFO | 4,474 | $360.67 | $92.4B | -23.28% | +20.61% | $1.6M | +0.00% | — | Sell Now |
| Aug 6, 2024 | Sell | HCA | Samuel N Hazen | CEO | 58,652 | $352.93 | $92.4B | -23.28% | +20.61% | $20.7M | +0.00% | — | Sell Now |
| Aug 5, 2024 | Sell | HCA | Joseph A Iii Sowell | SVP; Chief Development Officer | 26,734 | $350.18 | $92.4B | -23.28% | +20.61% | $9.4M | +0.00% | — | Sell Now |
| Jul 31, 2024 | Buy | HCA | Timothy M Mcmanus | Group President | 11,419 | $175.26 | $92.4B | -23.28% | +20.61% | $2.0M | +5.79% | — | Sell Now |
| Jul 29, 2024 | Sell | HCA | Deborah M Reiner | SVP - Mktg. & Communications | 3,314 | $359.96 | $92.4B | -23.28% | +20.61% | $1.2M | -48.56% | — | Sell Now |
| Jul 29, 2024 | Sell | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 18,424 | $263.68 | $92.4B | -23.28% | +20.61% | $4.9M | -3.23% | — | Sell Now |
| Jul 25, 2024 | Sell | HCA | Kathryn A. Torres | SVP-Payer Contracting & Align. | 1,857 | $355.05 | $92.4B | -23.28% | +20.61% | $659.3K | -9.47% | — | Sell Now |
| Jul 25, 2024 | Buy | HCA | Christopher F. Wyatt | SVP & Controller | 18,578 | $228.42 | $92.4B | -23.28% | +20.61% | $4.2M | +0.02% | — | Sell Now |
| May 16, 2024 | Sell | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 10,790 | $231.85 | $92.4B | -23.28% | +20.61% | $2.5M | -2.20% | — | Sell Now |
| May 15, 2024 | Sell | HCA | Kathryn A. Torres | SVP-Payer Contracting & Align. | 1,863 | $326.18 | $92.4B | -23.28% | +20.61% | $607.7K | -8.68% | — | Sell Now |
| May 15, 2024 | Buy | HCA | Joseph A Iii Sowell | SVP; Chief Development Officer | 28,908 | $157.39 | $92.4B | -23.28% | +20.61% | $4.5M | +33.00% | — | Sell Now |
| May 15, 2024 | Buy | HCA | Jon M Foster | EVP and COO | 60,723 | $165.29 | $92.4B | -23.28% | +20.61% | $10.0M | +15.57% | — | Sell Now |
| May 15, 2024 | Buy | HCA | Jon M Foster | EVP and COO | 108,112 | $101.05 | $92.4B | -23.28% | +20.61% | $10.9M | +6.66% | — | Sell Now |
| May 9, 2024 | Sell | HCA | Jeffrey E. Cohen | SVP-Government Relations | 1,650 | $313.00 | $92.4B | -23.28% | +20.61% | $516.5K | -24.14% | — | Sell Now |
| May 9, 2024 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 6,311 | $316.88 | $92.4B | -23.28% | +20.61% | $2.0M | -17.56% | — | Sell Now |
| May 9, 2024 | Sell | HCA | Erol R Akdamar | Group President | 10,278 | $321.89 | $92.4B | -23.28% | +20.61% | $3.3M | +0.00% | — | Sell Now |
| May 6, 2024 | Buy | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 37,109 | $187.89 | $92.4B | -23.28% | +20.61% | $7.0M | +0.13% | — | Sell Now |
| May 2, 2024 | Sell | HCA | Kathryn A. Torres | SVP-Payer Contracting & Align. | 1,863 | $312.00 | $92.4B | -23.28% | +20.61% | $581.3K | -4.08% | — | Sell Now |
| May 1, 2024 | Sell | HCA | Mike A Marks | EVP and CFO | 566 | $309.44 | $92.4B | -23.28% | +20.61% | $175.1K | -4.76% | — | Sell Now |
| Mar 18, 2024 | Sell | HCA | Chad J Wasserman | SVP and CIO | 4,544 | $222.92 | $92.4B | -23.28% | +20.61% | $1.0M | -2.24% | 10b5-1 | Sell Now |
| Feb 16, 2024 | Sell | HCA | Chad J Wasserman | SVP and CIO | 499 | $308.55 | $92.4B | -23.28% | +20.61% | $154.0K | -20.63% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Phillip G Billington | SVP-Internal Audit Services | 1,022 | $308.55 | $92.4B | -23.28% | +20.61% | $315.3K | -1.91% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Mike A Marks | SVP-Finance | 1,022 | $308.55 | $92.4B | -23.28% | +20.61% | $315.3K | -26.72% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 1,023 | $308.55 | $92.4B | -23.28% | +20.61% | $315.6K | -7.48% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Sammie S Mosier | SVP & Chief Nurse Executive | 1,068 | $308.55 | $92.4B | -23.28% | +20.61% | $329.5K | -9.31% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Jeffrey E. Cohen | SVP-Government Relations | 1,359 | $308.55 | $92.4B | -23.28% | +20.61% | $419.3K | -16.59% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Deborah M Reiner | SVP - Mktg. & Communications | 1,510 | $308.55 | $92.4B | -23.28% | +20.61% | $465.9K | -18.12% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Richard A Hammett | Group President | 1,762 | $308.55 | $92.4B | -23.28% | +20.61% | $543.7K | -8.95% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Kathryn A. Torres | SVP-Payer Contracting & Align. | 1,976 | $308.55 | $92.4B | -23.28% | +20.61% | $609.7K | -7.81% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Christopher F. Wyatt | SVP & Controller | 1,976 | $308.55 | $92.4B | -23.28% | +20.61% | $609.7K | -4.66% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Timothy M Mcmanus | Group President | 2,002 | $308.55 | $92.4B | -23.28% | +20.61% | $617.7K | -7.87% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Joseph A Iii Sowell | SVP; Chief Development Officer | 2,005 | $308.55 | $92.4B | -23.28% | +20.61% | $618.6K | -31.93% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Erol R Akdamar | Group President | 2,561 | $308.55 | $92.4B | -23.28% | +20.61% | $790.2K | -33.26% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Jennifer Berres | SVP & Chief Human Res. Officer | 3,240 | $308.55 | $92.4B | -23.28% | +20.61% | $999.7K | -14.75% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Jon M Foster | EVP and COO | 5,950 | $308.55 | $92.4B | -23.28% | +20.61% | $1.8M | -21.42% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 6,212 | $308.55 | $92.4B | -23.28% | +20.61% | $1.9M | -14.82% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Bill B Rutherford | CFO and EVP | 8,177 | $308.55 | $92.4B | -23.28% | +20.61% | $2.5M | -26.87% | — | Sell Now |
| Feb 16, 2024 | Sell | HCA | Samuel N Hazen | CEO | 30,387 | $308.55 | $92.4B | -23.28% | +20.61% | $9.4M | -10.26% | — | Sell Now |
| Feb 14, 2024 | Sell | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 349 | $305.43 | $92.4B | -23.28% | +20.61% | $106.6K | -3.40% | — | Sell Now |
| Feb 9, 2024 | Sell | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 4,262 | $306.21 | $92.4B | -23.28% | +20.61% | $1.3M | -29.37% | — | Sell Now |
| Feb 6, 2024 | Buy | HCA | Kathryn A. Torres | SVP-Payer Contracting & Align. | 3,515 | $227.25 | $92.4B | -23.28% | +20.61% | $798.8K | +1.54% | — | Sell Now |
| Feb 6, 2024 | Sell | HCA | Erol R Akdamar | Group President | 25,748 | $306.82 | $92.4B | -23.28% | +20.61% | $7.9M | +0.00% | — | Sell Now |
| Feb 5, 2024 | Sell | HCA | Christopher F. Wyatt | SVP & Controller | 4,000 | $312.42 | $92.4B | -23.28% | +20.61% | $1.2M | -9.67% | — | Sell Now |
| Feb 5, 2024 | Buy | HCA | Kathleen M Whalen | SVP & Chief Ethics Officer | 12,838 | $158.91 | $92.4B | -23.28% | +20.61% | $2.0M | +6.91% | — | Sell Now |
| Feb 2, 2024 | Sell | HCA | Chad J Wasserman | SVP and CIO | 690 | $311.90 | $92.4B | -23.28% | +20.61% | $215.2K | -46.38% | — | Sell Now |
| Feb 2, 2024 | Sell | HCA | Sammie S Mosier | SVP & Chief Nurse Executive | 13,104 | $272.43 | $92.4B | -23.28% | +20.61% | $3.6M | -0.62% | — | Sell Now |
| Feb 2, 2024 | Buy | HCA | Bill B Rutherford | CFO and EVP | 37,315 | $165.60 | $92.4B | -23.28% | +20.61% | $6.2M | +3.40% | — | Sell Now |
| Jan 31, 2024 | Sell | HCA | Michael S. Cuffe | EVP and Chief Clinical Officer | 3,928 | $249.93 | $92.4B | -23.28% | +20.61% | $981.7K | -5.64% | — | Sell Now |
| Jan 31, 2024 | Buy | HCA | Christopher F. Wyatt | SVP & Controller | 18,056 | $170.26 | $92.4B | -23.28% | +20.61% | $3.1M | +3.89% | — | Sell Now |
| Jan 31, 2024 | Sell | HCA | Kathryn A. Torres | SVP-Payer Contracting & Align. | 26,123 | $248.65 | $92.4B | -23.28% | +20.61% | $6.5M | -0.09% | — | Sell Now |
| Jan 29, 2024 | Sell | HCA | Sammie S Mosier | SVP & Chief Nurse Executive | 96 | $286.73 | $92.4B | -23.28% | +20.61% | $27.5K | -1.18% | — | Sell Now |
| Jan 29, 2024 | Sell | HCA | Richard A Hammett | Group President | 164 | $286.73 | $92.4B | -23.28% | +20.61% | $47.0K | -1.14% | — | Sell Now |
| Jan 28, 2024 | Sell | HCA | Michael R Mcalevey | SVP & Chief Legal Officer | 489 | $283.43 | $92.4B | -23.28% | +20.61% | $138.6K | -10.86% | — | Sell Now |
| Nov 13, 2023 | Buy | HCA | Erol R Akdamar | Group President | 40,776 | $110.25 | $92.4B | -23.28% | +20.61% | $4.5M | +47.99% | — | Sell Now |
| Nov 10, 2023 | Buy | HCA | Phillip G Billington | SVP-Internal Audit Services | 18,262 | $111.10 | $92.4B | -23.28% | +20.61% | $2.0M | +5.78% | — | Sell Now |
| Nov 10, 2023 | Sell | HCA | Joseph A Iii Sowell | SVP; Chief Development Officer | 129,402 | $232.82 | $92.4B | -23.28% | +20.61% | $30.1M | +0.00% | — | Sell Now |